作者: Richard P. Dutton , Michael Parr , Bartholomew J. Tortella , Howard R. Champion , Gordon R. Bernard
DOI: 10.1097/TA.0B013E31821A42CF
关键词:
摘要: Background:Safety data on recombinant activated factor VII (rFVIIa, NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark) in actively hemorrhaging trauma patients are limited. We present detailed safety from a large multicenter, randomized, placebo-controlled phase III study (the CONTROL trial).Metho